1. Drug-Receptor Theory

Clark applied the law of mass action to drug-receptor binding. Consider a drug D binding reversibly to a receptor R to form a drug-receptor complex DR:

At equilibrium, the rate of association equals the rate of dissociation:

Defining the dissociation constant $K_d = k_{-1}/k_1$, and letting the total receptor concentration be $[R_T] = [R] + [DR]$:

Solving for the fractional occupancy $\rho = [DR]/[R_T]$:

Clark's key assumption was that response is directly proportional to occupancy:

This is the Langmuir isotherm applied to pharmacology. At $[D] = K_d$, exactly 50% of receptors are occupied, predicting the characteristic hyperbolic dose-response curve. The $K_d$ has units of concentration and represents the drug's affinity: lower $K_d$ means higher affinity.

Ariens recognized that Clark's model could not explain partial agonists -- drugs that produce submaximal responses even at full receptor occupancy. He introduced intrinsic activity $\alpha$ (ranging from 0 to 1):

For a full agonist, $\alpha = 1$; for a partial agonist,$0 < \alpha < 1$; for an antagonist, $\alpha = 0$. The maximum achievable response for any drug is:

When a partial agonist (drug A with $\alpha_A < 1$) competes with a full agonist (drug B with $\alpha_B = 1$) at the same receptor:

This explains the "dual agonist-antagonist" behavior of partial agonists: they stimulate receptors when alone but reduce the response when competing with a full agonist. Clinical examples include buprenorphine (partial mu-opioid agonist) and pindolol (partial beta-adrenergic agonist).

A.V. Hill (1910) developed his equation to describe the cooperative binding of oxygen to hemoglobin. In pharmacology, it accounts for cooperative drug-receptor interactions and signal amplification. Consider $n$ drug molecules binding simultaneously:

The equilibrium expression gives:

Following the same derivation as Clark but with $[D]^n$:

The Hill coefficient $n$ (also called $n_H$) determines the steepness of the curve. Taking the logarithm:

A Hill plot of $\log(E/(E_{\max}-E))$ vs $\log[D]$ yields a straight line with slope $n$. When $n = 1$, the equation reduces to simple Michaelis-Menten kinetics. When $n > 1$, positive cooperativity creates a steeper dose-response curve (ultrasensitive switch-like behavior). When $n < 1$, negative cooperativity produces a shallower curve.

Heinz Otto Schild derived the quantitative relationship for competitive antagonism. In the presence of a competitive antagonist B at concentration $[B]$, the agonist must compete for the same binding site. The apparent $K_d$ becomes:

The dose ratio (DR) is the factor by which the agonist concentration must increase to produce the same response in the presence of antagonist:

This is the Schild equation. Taking the logarithm:

The Schild plot of $\log(DR-1)$ vs $\log[B]$ gives a straight line with slope = 1 for competitive antagonism. The x-intercept gives:

The $pA_2$ value is the negative logarithm of the antagonist concentration that produces a dose ratio of 2 (i.e., doubles the agonist $EC_{50}$). A slope significantly different from 1 suggests non-competitive mechanisms, receptor heterogeneity, or removal of antagonist from the biophase.

James Black and Paul Leff (1983) developed the operational model to unify affinity and efficacy without assuming a linear stimulus-response relationship. They assumed a hyperbolic (Michaelis-Menten) transducer function:

Where $K_E$ is the concentration of drug-receptor complex producing 50% of the system maximum. Substituting $[DR] = [R_T][D]/(K_A + [D])$and defining $\tau = [R_T]/K_E$ (the transducer ratio):

From this equation, the observed $EC_{50}$ and maximum response are:

The parameter $\tau$ encapsulates both receptor density and coupling efficiency. High $\tau$ (large receptor reserve) means:

• $EC_{50} \ll K_A$ -- the drug appears more potent than its binding affinity suggests
• $E_{\text{obs,max}} \to E_{\max}$ -- near-maximal system response
• Many receptors are "spare" -- not needed for maximal response

The operational model is superior to earlier models because it separates system-independent parameters ($K_A$, intrinsic efficacy) from system-dependent parameters ($\tau$, $E_{\max}$), allowing comparison of drug activity across different tissues and assay systems.